Mobile App

Google Play Apple Store
Hot Topics on CAR T- Cell Therapy from the 63rd ASH Annual Meeting*
Certified AMA Activity - Clinical Clips
The introduction of chimeric antigen receptor (CAR) T-cell therapies has shifted the paradigm for several incurable and refractory hematologic malignancies and currently various cellular immunotherapies are under investigation. To ensure updated ongoing care for patients, clinicians need to be familiar with recent clinical trial evidence on approved and emerging CAR T-cell therapies.

This educational Clinical Clip focused on CAR T-cell approaches has summarized key data presented at the 63rd American Society of Hematology (ASH) Annual Meeting.
Review the video to claim AMA credit after completion of the brief Post-Test/Evaluation.
Michael Wang, MD
Michael Wang, MD
Endowed Professor
Department of Lymphoma/Myeloma,
Department of Stem Cell Transplantation and Cellular Therapy
University of Texas MD Anderson Cancer Center

*This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings of the 2021 American Society of Hematology Annual Meeting (ASH)
Supported by an independent educational grant from Bristol Myers Squibb

Launch Date: December 17, 2021
Release Date: December 17, 2021
Expiration Date: November 30, 2022

November 30, 2022
Mini Module


Change Settings